Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-17 · accession 0001209191-23-011686 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-22 | 2023-02-17 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $292.85 | -9,359 | 139.4K | -6% | -$2.74M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-17 | F | D | 9,359 | $292.85 | 139,355 | D | — | — |